HCA Healthcare (HCA) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $7.22
- Estimate
- $6.63
- Surprise
- +8.9%
- Revenue (period 2026-09-30)
- $19.85B
- Score at report (before → after)
- 5.8 → 5.7/10
Revenue source: xbrl.
How the report landed
HCA Healthcare (HCA) beat the $6.63 estimate with adjusted EPS of $7.22 — a clear 8.9% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.8/10) to Hold at 5.7/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates HCA Sell at 5.3/10.
4 of the last 4 quarters beat the estimate; this quarter's +8.9% surprise compares with a +4.4% four-quarter average. Next scheduled report: 2027-01-26.
What supports the rating
- Strong earnings beat streak (4/4)
- Margin of safety: 31%
What argues against it
- Analyst target reached - limited upside remaining
- Weak growth
- Target reached (-13.0% upside)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $500.34
- Stop
- $467.84
At 17.0× trailing and 16.3× forward earnings, consensus estimates imply little change in earnings power.
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
HCA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Care Facilities
- Market cap
- $106.91B
- P/E (fwd)
- 16.3
- P/E (ttm)
- 17.0
- 52-week range
- $353.99–$556.52
- Off 52-week high
- 10.1%
- RSI (14)
- 64
- Volume vs avg
- 0.36×
- Score today
- 5.3/10